ReviewGut2021
Gut microbiota-derived metabolites as central regulators in metabolic disorders.
Review in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 763 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
763 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,207 citations in OpenAlex.
- Effects of Weight Loss Interventions on Gut Microbiota-Derived Metabolites Linked to Cardiometabolic Health: A Systematic Review and Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- Causal role of genetically predicted impairment of branched-chain amino acid catabolism on insulin secretion and insulin resistance in type 2 diabetes.Diabetes, obesity & metabolism · 2026Pooled it
- Probiotics and prebiotics as alternatives to antibiotics in aquaculture: a systematic and bibliometric review of antimicrobial and antioxidant mechanisms.Frontiers in microbiology · 2026Pooled it
- Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.Journal for immunotherapy of cancer · 2026Trial
- Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.Clinical and molecular hepatology · 2026Trial
- A yeast-derived postbiotic fermentate rapidly modulates inflammatory cytokines and immune surveillance markers in healthy adults: a randomized double-blind placebo-controlled cross-over trial.Frontiers in nutrition · 2026Trial
- Gut microbiome and pregnancy complications: emerging evidence and mechanistic insights.Gut microbes · 2026Review
- Glucagon-like peptide-1: a critical link between gut microbiota dysbiosis and degenerative musculoskeletal diseases.Gut microbes · 2026Review
- Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy.Gut microbes · 2026Article
- Gut microbiome in type 2 diabetes: insights from metagenomics, multi-omics, and diet-microbe interactions.Gut microbes · 2026Review
- Gut microbiota metabolic reprogramming drives the development of metabolic diseases in the host.Gut microbes · 2026Review
- Compound probiotics alleviateVirulence · 2026Article
- Metataxonomic strategy to decipher gut bacteriome biomarkers of type 2 diabetes and obesity in Tunisian population.Bioscience reports · 2026Article
- Targeted Strategies of Adipose Stem Cells for Metabolic Diseases: Mechanisms and Clinical Translation Challenges.Stem cell reviews and reports · 2026Review
- D-Psicose Attenuates Hepatic Steatosis and Inflammatory Injury in HFD/STZ-Induced T2DM Mice and Is Associated With Alterations in Gut Microbiota, Tryptophan Metabolism, and Hepatic AhR-Related Signaling.Food science & nutrition · 2026Article
- The FERM guild: a differentially correlated microbial module drives hypertension via metabolic flux perturbations.mSystems · 2026Article
- Hemp seed oil ameliorates DSS-induced ulcerative colitis in mice by altering transcriptomics and metabolomics.Journal of natural medicines · 2026Article
- Microbiota-Associated Amino Acid Metabolites in Inflammatory Bowel Disease: Emerging Key Players in the Host-Microbe Interface.Microorganisms · 2026Review
- Gestational Low-Dose Bisphenol A Exposure Enhances Susceptibility to Metabolic Disorders in Adult Offspring Mice: Role of the Gut Microbiota-SCFAs-GPRs Axis.Environment & health (Washington, D.C.) · 2026Article
- Effects of Bioactive Microalgal Pigment Intake on Metabolic Parameters, Cecal Distribution and Short-Chain Fatty Acids in a Diabetic Rat Model.Life (Basel, Switzerland) · 2026Article
703 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic disorders represent a growing worldwide health challenge due to their dramatically increasing prevalence. The gut microbiota is a crucial actor that can interact with the host by the production of a diverse reservoir of metabolites, from exogenous dietary substrates or endogenous host compounds. Metabolic disorders are associated with alterations in the composition and function of the gut microbiota. Specific classes of microbiota-derived metabolites, notably bile acids, short-chain fatty acids, branched-chain amino acids, trimethylamine N-oxide, tryptophan and indole derivatives, have been implicated in the pathogenesis of metabolic disorders. This review aims to define the key classes of microbiota-derived metabolites that are altered in metabolic diseases and their role in pathogenesis. They represent potential biomarkers for early diagnosis and prognosis as well as promising targets for the development of novel therapeutic tools for metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.